文献速递神经肿瘤

胶质瘤术后6个月通用健康相关生活质量是否存在反应转移

Is there a response shift in generic health-related quality of life 6 months after glioma surgery?
PubMed 文献 · Acta Neurochir (Wien) · 2016-12-07

本研究纳入73例胶质瘤患者,术前及术后6个月用EuroQol-5D 3L评估通用健康相关生活质量,随访时用then-test回顾基线。平均而言未见反应转移,但生活质量改善或恶化者then-test指数与基线相差0.10-0.13,反应转移似乎削弱了生活质量变化的影响。

要点

  • 73例胶质瘤患者术前及术后6个月完成EQ-5D 3L评估,随访时用then-test回顾基线。
  • then-test指数与基线均值相似(均差0.01,95%CI -0.57至0.07,p=0.82)。
  • 生活质量改善或恶化者then-test指数与基线相差0.10-0.13,反应转移似乎削弱变化影响。

核心结论

  • 平均而言,在能参与术后6个月评估的胶质瘤患者中,EQ-5D 3L未观察到反应转移。
  • 随访时生活质量发生变化者,反应转移似乎通过恶化者降低内在标准、改善者提高标准来削弱生活质量变化的影响。

研究设计与样本

  • 健康相关生活质量研究,纳入胶质瘤患者,术前及术后6个月用EuroQol-5D 3L评估通用健康相关生活质量。
  • 随访时患者用同一问卷回顾性评分其基线健康相关生活质量(then-test)。
  • 2013年1月至2015年9月共纳入73例患者。

主要发现

  • then-test法平均EQ-5D 3L指数与基线相似(均差0.01,95%CI -0.57至0.07,p=0.82)。
  • then-test与基线VAS评分相似(均差0,95%CI -7至7,p=0.97)。
  • 随访时健康相关生活质量改善或恶化者,then-test EQ-5D 3L指数值与基线相差0.10-0.13。
  • then-test观察到的变化方向与临床变化方向相似,削弱了基线至随访健康相关生活质量变化的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients may recalibrate internal standards when faced with a serious diagnosis or neurological deficits. This so-called response shift is important to understand in longitudinal health-related quality of life (HRQoL) data, but this is not quantitatively assessed in glioma patients. METHODS: Patients with gliomas were eligible for this HRQoL study. We used EuroQol-5D 3 L to assess generic HRQoL with assessment preoperatively and at 6 months postoperatively. At time of follow-up, patients scored how they considered their baseline HRQoL in retrospect using the same questionnaire ("then-test"). RESULTS: Seventy-three patients were enrolled between January 2013 and September 2015. With the then-test approach, the mean EQ-5D 3 L index was similar compared to baseline (0.77, mean difference 0.01, 95% CI -0.57 to 0.07, p = 0.82). Also, then-test and baseline VAS score were similar (mean difference 0, 95% CI -7 to 7, p = 0.97). However, a 0.10-0.13 difference from baseline was observed in patients that improved or deteriorated in HRQoL at follow-up according to the then-test EQ-5D 3 L index value. The direction of change as observed from the then-test was similar to the direction of clinical change, reducing the impact of any HRQoL change from baseline to follow-up. CONCLUSIONS: On average, we observed no response shift using EQ-5D 3 L in the selection of glioma patients able to participate at 6 months after surgery. However, following change in HRQoL at follow-up, response shift seems to reduce the effects of HRQoL changes by lowering of internal standards in patients that deteriorate and raising the standards in patients that improve.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Jakola AS, Solheim O, Gulati S, et al. Is there a response shift in generic health-related quality of life 6 months after glioma surgery? Acta Neurochir (Wien). 2016. PMID: 27928631. doi:10.1007/s00701-016-3040-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。